ArticleFrontiers in oncology2026
Case Report: Craniotomy and radiotherapy for multiple hemorrhagic cerebral lesions from resected cardiac myxoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report elaborates on a unique case of multiple cerebral lesions from completely resected atrial myxoma which was treated with craniotomy and radiotherapy. A 56-year-old female presented with progressive headache, left limb weakness and low-grade fever for over 20 days. She had undergone total resection of left atrial myxoma nine months before. MRI revealed multiple hemorrhagic lesions in both cerebral hemispheres and left cerebellum. The symptomatic lesion in the right parietal lobe was resected under neuronavigation, ultrasound and electrophysiological monitoring. Pathology confirmed myxoma seeding. Whole-brain radiotherapy (30 Gy in 15 fractions) was administered for the remaining multiple lesions. During 14 months of follow-up, the patient's left limb muscle strength improved from grade V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.